May 09, 2025 • Zacks Commentary
BULLISH
These AI Stocks Posted Robust Results: Time to Buy?
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
May 09, 2025 • Benzinga
NEUTRAL
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of market exclusivity, along with increasing government initiatives to promote the use of generic drugs.
May 09, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
How Much Upside is Left in Astrazeneca ( AZN ) ? Wall Street Analysts Think 27.89%
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
May 09, 2025 • Zacks Commentary
NEUTRAL
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
May 08, 2025 • Benzinga
NEUTRAL
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks 3 Pharma ETFs To Watch As Trump Turns Up The Heat On Drugmakers - AstraZeneca ( NASDAQ:AZN ) , iShares U.S. Pharmaceutical ETF ( ARCA:IHE )
Trump's push to tie Medicaid drug prices to lower international benchmarks could erase $1 trillion in revenues over 10 years. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
May 08, 2025 • Zacks Commentary
NEUTRAL
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.